Northwest Biotherapeutics (NWBO) Receivables (2012 - 2017)
Northwest Biotherapeutics' (NWBO) quarterly Receivables came in at $3.8 million in Q4 2017, little changed year-on-year from $3.8 million in Q4 2016, and little changed quarter-over-quarter from $3.8 million in Q2 2017.
Northwest Biotherapeutics (NWBO) Receivables (2012 - 2017) Analysis & Trends
Northwest Biotherapeutics' Receivables history runs 3 years deep, the most recent figure standing at $3.8 million for Q4 2017.
- On a quarterly basis, Receivables changed 0.0% year-over-year to $3.8 million in Q4 2017; TTM through Dec 2017 was $3.8 million, a 0.0% change from a year earlier, with the FY2017 full-year figure at $3.8 million, changed 0.0% from the prior year.
- Receivables was little changed at $3.8 million in Q4 2017 per NWBO's latest filing, from $3.8 million in the prior quarter.
- Across five years, Receivables topped out at $3.8 million in Q4 2016 and bottomed at $3.8 million in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 4.97 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 938.02 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.13 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.93 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Northwest Biotherapeutics | 253,653.43 | -1.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 3.75 Mn |
| Jun 30, 2017 | 3.75 Mn |
| Dec 31, 2016 | 3.75 Mn |
| Jun 30, 2012 | 195,000.00 |